iX Biopharma gets Israel patent for drug delivery technology
CATALIST-LISTED iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology, it said in a bourse filing on Monday.
The patent, which expires on Oct 11, 2033, will provide key intellectual property protection for the company's WaferiX delivery technology platform in the country, it added.
In its filing, iX Biopharma also said it had been issued a patent for WaferiX in the US, which will expire on Oct 26, 2030. This follows the company's June 9 announcement that it had received a notice of allowance from the United States Patent and Trademark Office for the technology.
With the Israel patent, the intellectual property rights for iX Biopharma's sublingual wafer technology is now secured in all key markets, including the US, China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia and Indonesia, the pharmaceutical company said.
WaferiX is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (placed under the tongue) and delivered "safely, conveniently and rapidly" into the bloodstream, it added.
Shares of iX Biopharma ended Friday flat at S$0.22.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Mapletree Industrial Trust Q4 DPU rises 0.9% to S$0.0336
Nasdaq’s profit falls as shaky economy keeps IPO revival elusive
iFast Q1 net profit surges on ePension unit performance
Suntec Reit Q1 DPU down 13% to S$0.01511 in absence of capital distribution
US: Wall St opens lower as Meta Platforms, economic data weigh
Sheng Siong Q1 net profit up 9.3% on higher revenue